Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LMF237 add-on to vildagliptin in type 2 diabetes inadequately controlled on vildagliptin monotherapy
jRCT2080222046Phase 3
- Sponsor
- Novartis
- Start
- Mar 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of vildagliptin + metformin in type 2 diabetes mellitus (T2DM) (3 arms), sponsored by Novartis.
02
Drugs
vildagliptin + metformin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on jRCT2080222046.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080222046.